Kenvue, a Johnson & Johnson spinoff, offers long-term upside with solid dividends despite near-term economic headwinds. Read ...

Kenvue on Thursday forecast that its annual profit would be flat year-over-year as the consumer health firm anticipates a ...

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday as strong demand for its cough-and-cold ...

The leadership change comes at the end of a week in which the California-based toymaker landed squarely in the crosshairs of ...

Shares of Kenvue rose in premarket trading Thursday after the maker of Band-Aid, Tylenol, and Listerine reported ...

(NYSE: KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our ...

Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

The stock's rise snapped a three-day losing streak.

The Neutrogena and Aveeno owner has also increased its 2025 full-year outlook to reflect the impact of costs associated with ...

Hello, and welcome to the Kenvue First Quarter 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a ...

This was the stock's third consecutive day of losses.

May 8 (Reuters) - Kenvue (KVUE.N), opens new tab on Thursday forecast that its annual profit would be flat year-over-year as the consumer health firm anticipates a $150 million impact from ...